Allovir, Inc. Files 8-K on Security Holder Rights
Ticker: KLRS · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Allovir, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing-update
TL;DR
Allovir filed an 8-K on Jan 15, 2025, impacting security holder rights and corporate docs.
AI Summary
On January 15, 2025, Allovir, Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, indicating significant corporate actions or updates for the company, formerly known as ViraCyte, Inc.
Why It Matters
This filing signals potential changes affecting Allovir's shareholders and corporate structure, requiring investors to review the updated terms and conditions.
Risk Assessment
Risk Level: medium — Filings related to modifications of security holder rights and amendments to corporate documents can introduce uncertainty and potential changes in shareholder value.
Key Players & Entities
- Allovir, Inc. (company) — Registrant
- ViraCyte, Inc. (company) — Former company name
- January 15, 2025 (date) — Date of earliest event reported
FAQ
What specific material modifications were made to the rights of Allovir, Inc.'s security holders?
The filing indicates material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary information of the 8-K.
What are the key amendments to Allovir, Inc.'s articles of incorporation or bylaws mentioned in the filing?
The 8-K report states that there were amendments to the articles of incorporation or bylaws, but the specific content of these amendments is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 15, 2025.
What was Allovir, Inc.'s former company name?
Allovir, Inc.'s former company name was ViraCyte, Inc.
What is Allovir, Inc.'s state of incorporation and fiscal year end?
Allovir, Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Filing Stats: 1,688 words · 7 min read · ~6 pages · Grade level 13.5 · Accepted 2025-01-15 16:39:57
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALVR The Nasdaq
Filing Documents
- d900097d8k.htm (8-K) — 36KB
- d900097dex31.htm (EX-3.1) — 10KB
- 0001193125-25-007077.txt ( ) — 180KB
- alvr-20250115.xsd (EX-101.SCH) — 3KB
- alvr-20250115_lab.xml (EX-101.LAB) — 19KB
- alvr-20250115_pre.xml (EX-101.PRE) — 12KB
- d900097d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Third Amended and Restated Certificate of Incorporation of AlloVir, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AlloVir, Inc. Date: January 15, 2025 By: /s/ Edward Miller Name: Edward Miller Title: General Counsel